Lung neuroendocrine tumours (typical and atypical carcinoid)

What changed: Lung neuroendocrine tumours (typical and atypical carcinoid)

Indication page →

Every dated change on the records linked to Lung neuroendocrine tumours (typical and atypical carcinoid), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval2Trial result2Milestone6This record1

FollowWatch this record and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordLung neuroendocrine tumours (typical and atypical carcinoid)
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 1

2025MilestoneCabozantinib
Cabozantinib approved for previously treated neuroendocrine tumours including lung; ESMO subgroup analysis
A milestone in how this cancer is treated.

2024 · 2

2017 · 1

2017MilestoneLung neuroendocrine tumours (typical and atypical carcinoid)
LUNA: pasireotide and everolimus active in lung and thymic tumours
A milestone in how this cancer is treated.

2016 · 1

2016MilestoneRADIANT-3 and RADIANT-4
RADIANT-4: everolimus approved for lung neuroendocrine tumours
A milestone in how this cancer is treated.

2015 · 1

2015MilestoneNeuroendocrine tumour grade (Ki-67) and WHO classification
WHO lung classification groups carcinoids with small-cell and large-cell neuroendocrine carcinoma as neuroendocrine tumours
A milestone in how this cancer is treated.

2014 · 1

2014ApprovalPasireotide
Pasireotide approved in US
Acromegaly inadequately controlled by surgery or for whom surgery is not an option (long-acting depot)

2012 · 1

2012ApprovalPasireotide
Pasireotide approved in US
Cushing's disease when pituitary surgery is not an option or has not been curative

2011 · 1

2011Trial resultRADIANT-3 and RADIANT-4
RADIANT-3 and RADIANT-4 reported
PFS HR 0.

1972 · 1

1972MilestoneLung neuroendocrine tumours (typical and atypical carcinoid)
Arrigoni defines atypical carcinoid as a separate entity
A milestone in how this cancer is treated.